Gilead Sciences and Korean CDMO Yuhan Enter $140 Million API Supply Agreement

May 23, 2026 10:29 CST Updated 10:30

Gilead Sciences

Antiviral Drug Developer

YUHAN

Pharmaceutical Manufacturer

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only provides an introduction to drugs related to medical health, not a recommendation for treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircle DataMonitoring Shows: On May 20, 2026, U.S.-based Gilead Sciences expanded its collaboration with South Korea's integrated pharmaceutical company Yuhan Co., Ltd. The two parties reached an active pharmaceutical ingredient (API) supply agreement worth 210 billion Korean won (approximately 140 million U.S. dollars). Specific product details were not disclosed.

The agreement is valid until the end of 2027, and relevant information was disclosed this week through a regulatory announcement (in Korean) by the Korea Exchange (KRX).

This transaction amount accounts for 9.6% of Yuhan's revenue in 2025. Yuhan has two API production bases in Korea and is experiencing rapid business growth, with overseas sales in the first quarter of 2026 increasing by 21% year-over-year.

Gilead and Yuhan have had multiple CDMO API collaborations in the past.

Yuhan Corporation (000100.KS): A well-established South Korean pharmaceutical company (founded in 1926), with business coverageInnovative Drug R&D, Generic Drugs, API/CDMOThree major segments; approximately [amount] in revenue by 2025KRW 2.19 trillion, with its subsidiary Yuhan Chemical (Yuhan Chemical) as the core API/CDMO company.

LECLAZA® (Lazertinib)：Third-generation EGFR-TKI, First-line / Second-line Treatment for Non-Small Cell Lung Cancer (NSCLC);Global Launch in 2024, in collaboration with Janssen (Johnson & Johnson).

In the early pipeline: Autoimmune IgE Fc fusion protein / MASH GLP-1/FGF21 dual agonist / Rare disease drug GCS inhibitor under development.

References:

PharmaCircle Data;

https://www.prnewswire.com/news-releases/whitehawk-therapeutics-expands-adc-pipeline-with-new-option-agreement-for-use-of-cpt113-linker-payload-302779285.html；

https://www.prnewswire.com/news-releases；

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

https://www.biotechtv.com/post；

https://www.prnewswire.com；

；Etc.